Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pluripotent, but not quite global

As the U.S. government and NIH debate whether federal funding should be permitted for research involving the derivation or use of pluripotent human embryonic stem (ES) cells, academic researchers elsewhere in the world are finding fewer restrictions on their work. Thus academic research in the U.S. runs the risk of falling behind both privately funded interests

Read the full 567 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE